<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9108337</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21207</journal-id>
<journal-id journal-id-type="nlm-ta">Trends Cardiovasc Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Trends Cardiovasc. Med.</journal-id>
<journal-title-group>
<journal-title>Trends in cardiovascular medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1050-1738</issn>
<issn pub-type="epub">1873-2615</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29661707</article-id>
<article-id pub-id-type="pmc">6590899</article-id>
<article-id pub-id-type="doi">10.1016/j.tcm.2018.03.003</article-id>
<article-id pub-id-type="manuscript">NIHMS985430</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The genetic architecture of long QT syndrome: A critical reappraisal</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Giudicessi</surname>
<given-names>John R.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilde</surname>
<given-names>Arthur A.M.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ackerman</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Cardiovascular Medicine (Cardiovascular Diseases Fellowship and Clinician-Investigator Training
Programs), Mayo Clinic, Rochester, MN, United States</aff>
<aff id="A2"><label>b</label>Department of Medicine (Division of Cardiology), Columbia University Irving Medical Center, New York, NY,
United States</aff>
<aff id="A3"><label>c</label>Department of Clinical &amp; Experimental Cardiology, Academic Medical Center, University of Amsterdam,
Amsterdam, The Netherlands</aff>
<aff id="A4"><label>d</label>Departments of Cardiovascular Medicine (Division of Heart Rhythm Services), Pediatrics (Division of Pediatric
Cardiology), and Molecular Pharmacology &amp; Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo
Clinic, Rochester, MN, United States</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Corresponding author. Long QT Syndrome/Genetic Heart Rhythm Clinic and Windland Smith Rice Sudden
Death Genomics Laboratory, Guggenheim 501, Mayo Clinic, Rochester, MN 55905, United States.
<email>ackerman.michael@mayo.edu</email> (M.J. Ackerman).</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P44"><bold>Conflict of interest statement</bold>: Dr. Ackerman is a consultant for Audentes Therapeutics, Boston Scientific,
Gilead Sciences, Invitae, Medtronic, MyoKardia, and St. Jude Medical. From 2004 to 2016, M.J.A. and Mayo Clinic received
sales-based royalties from Transgenomic for their FAMILION-LQTS and FAMILION-CPVT genetic tests. Currently, M.J.A. and Mayo Clinic
have royalty/equity relationships (without remuneration so far) with AliveCor, Blue Ox Health, and StemoniX. However, none of
these entities participated in this study. Drs. Giudicessi and Wilde declare no conflicts.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>24</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>28</volume>
<issue>7</issue>
<fpage>453</fpage>
<lpage>464</lpage>
<!--elocation-id from pubmed: 10.1016/j.tcm.2018.03.003-->
<abstract id="ABS1">
<p id="P1">Collectively, the completion of the Human Genome Project and subsequent development of high-throughput next-generation
sequencing methodologies have revolutionized genomic research. However, the rapid sequencing and analysis of thousands upon
thousands of human exomes and genomes has taught us that most genes, including those known to cause heritable cardiovascular
disorders such as long QT syndrome, harbor an unexpected background rate of rare, and presumably innocuous, non-synonymous genetic
variation. In this Review, we aim to reappraise the genetic architecture underlying both the acquired and congenital forms of long
QT syndrome by examining how the clinical phenotype associated with and background genetic variation in long QT
syndrome-susceptibility genes impacts the clinical validity of existing gene-disease associations and the variant classification
and reporting strategies that serve as the foundation for diagnostic long QT syndrome genetic testing.</p>
</abstract>
<kwd-group>
<kwd>Arrhythmia</kwd>
<kwd>Genetic testing</kwd>
<kwd>Genetic variation</kwd>
<kwd>Long QT syndrome</kwd>
<kwd>Sudden cardiac death</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>